News

Oryn Therapeutics and Keck Medicine of USC RECEIVE $5.3 M NIH award

By | Award, Bacterial Infections, News | No Comments

Oryn Therapeutics and Keck Medicine of USC will collaborate on a $5.3 M National Institute of Health award to develop new drugs to treat multi-drug resistant bacterial infections. In response to a call to develop novel solutions to the crisis of drug-resistant bacterial infections, scientists at Oryn and USC will join forces to exploit Oryn’s macrocyclic peptide technologies to identify and produce novel drugs that kill pathogens that are increasingly implicated in lethal infections. The collaboration will be led by USC Professor and Oryn co-founder Michael Selsted, USC Professor Andre Ouellette, and Oryn scientists.

Oryn therapeutics secures $3,000,000 of angel investment

By | Investment, News | No Comments

Mark Armenante, Founder and Board Member of Vlocity invests $1.5M in Oryn Therapeutics. Young Sohn, Founder and Board Member of Vlocity invests $1.5M in Oryn Therapeutics. This funding, along with the first ever Direct to Phase II SBIR award of $1.5M from The National Institute of Health will propel Oryn Therapeutics into Phase 1 clinical trials of the company’s novel rheumatoid arthritis drug.